Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Recent & Breaking News (NYSEAM:TOVX)

Synthetic Biologics' Webcast Conference Call Set for 9:00 a.m. EST this Morning, December 9th

PR Newswire December 9, 2013

Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes

PR Newswire December 7, 2013

Synthetic Biologics to Present at the LD MICRO VI: Main Event Conference in Los Angeles

PR Newswire December 2, 2013

Synthetic Biologics' SYN-004 for the Prevention of C. difficile Infections Named a "Top Project to Watch" by Elsevier Business Intelligence

PR Newswire November 14, 2013

Synthetic Biologics Reports Third Quarter 2013 Financial Results and Operational Update

PR Newswire November 14, 2013

Synthetic Biologics to Report Third Quarter 2013 Financial Results

PR Newswire November 7, 2013

Synthetic Biologics Initiates Manufacturing of SYN-004 for Use in Preclinical and Clinical Trials to Target the Prevention of C. difficile Infections

PR Newswire October 15, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on CL, MKTO, ORBC and SYN

Accesswire October 1, 2013

Synthetic Biologics Responds to Recent CDC Report on Threat of "Super Bugs"

PR Newswire September 20, 2013

Synthetic Biologics to Present at the First Global Life Sciences Conference in Warsaw, Poland

PR Newswire September 10, 2013

Synthetic Biologics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City

PR Newswire September 3, 2013

Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update

PR Newswire August 14, 2013

Synthetic Biologics to Report Second Quarter 2013 Financial Results

PR Newswire August 8, 2013

Former Pfizer/Wyeth Global Infectious Disease Pharmaceutical Executive, Lewis Barrett, Appointed Senior Vice President, Commercial Strategy of Synthetic Biologics, Inc.

PR Newswire August 6, 2013

Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program

PR Newswire July 18, 2013

Synthetic Biologics to Present at OneMedForum New York 2013

PR Newswire June 19, 2013

Synthetic Biologics to Host Multiple Sclerosis-Estriol Investor Day in New York City on June 25, 2013

PR Newswire June 13, 2013

Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference

PR Newswire May 21, 2013

Synthetic Biologics Reports First Quarter 2013 Financial Results

PR Newswire May 15, 2013

Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect

PR Newswire April 19, 2013